United States Tuberculosis Drug Market 2031 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global tuberculosis drug market size reached US$ 2.34 Billion in 2023 with a rise of US$ 2.45 Billion in 2024 and is expected to reach US$ 3.78 Billion by 2033, growing at a CAGR of 4.9% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/tuberculosis-drug-market?sb

Key Development:

United States: Recent Tuberculosis Drug Developments

✅ In November 2025, mid‐stage (Phase 2) clinical trial results for sorfequiline (TBAJ‐876) a next‐generation diarylquinoline antibiotic showed it had stronger anti‐TB activity than the current standard regimen and a favorable safety profile, potentially enabling shorter treatment durations for both drug‐sensitive and drug‐resistant TB.

✅ In November 2025, the TB Alliance highlighted that sorfequiline combined with pretomanid and linezolid in the SPaL regimen demonstrated superior effectiveness compared with existing therapy (HRZE), marking a key milestone toward an ultra‐short all‐oral TB regimen.

✅ In the past 3 months, Mumbai reported over 1,000 drug‐resistant TB patients successfully treated with the shorter six‐month BPaL‐M regimen (bedaquiline, pretomanid, linezolid ± moxifloxacin) a program under India's National TB Elimination Programme that builds on previously approved TB drugs and shows real‐world uptake and impact.

✅ In late 2025, disease‐burden reporting noted ongoing challenges in TB treatment accessibility and funding, underscoring the importance of new drug development and delivery innovations.

Japan: Recent Tuberculosis Drug Developments

✅ In November 2025, Otsuka Pharmaceutical began enrolling the first participants in a Phase 3 clinical trial of its investigational anti‐TB compound quabodepistat (OPC‐167832) for multidrug‐resistant pulmonary tuberculosis, aiming to evaluate efficacy, safety and tolerability of shorter, less toxic regimens.

✅ In November 2025, the QUANTUM‐TB Phase 3 study involving sites across Japan, the Philippines and other countries was launched to accelerate development of quabodepistat‐based regimens for fluoroquinolone‐sensitive and fluoroquinolone‐resistant MDR‐TB, marking a major clinical milestone.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=tuberculosis-drug-market

Europe: Recent Tuberculosis Drug & Treatment Developments

✅ In late 2025, clinical data from Phase 2 studies of sorfequiline evaluated internationally but with participation from European research partners emphasized its potential to outperform current anti‐TB drugs and accelerate the pathway to Phase 3 trials in 2026.

✅ In late 2025, European partnerships under initiatives like TRIC‐TB, bETo‐TB and UNITE4TB advanced development of new anti‐TB therapies, strengthening collaborative research aimed at improving treatment regimens and addressing drug resistance.

✅ In 2025, experts in Europe raised concern about emerging extensively drug‐resistant TB (XDR‐TB) and the need to preserve effectiveness of key drugs such as bedaquiline and linezolid while pushing for enhanced stewardship and novel therapeutics.

✅ In 2025, WHO‐supported regional workshops and policy discussions focused on implementing updated guidelines for drug‐resistant TB and improving access to key medicines, including bedaquiline‐containing regimens to optimize treatment protocols across European health systems.

Key Players:

=> Sanofi, LEDERLE PHARMACEUTICAL DIVISION, Hospira, Inc., Bayer AG, JAMP Pharma Corporation, Pfizer Inc., Mylan N.V., Otsuka Pharmaceutical, Lupin Limited, Macleods Pharmaceuticals, and Novartis AG, among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/tuberculosis-drug-market?sb

Key Segments:

By Therapy Type

First-line Drug Therapy - ~50% share

Widely used as initial treatment for both latent and active TB; high adoption in hospitals and government health programs.

Second-line Drug Therapy - ~25% share

Used for drug-resistant TB cases or patients not responding to first-line drugs; moderate market penetration.

Combination Drugs Therapy - ~25% share

Growing adoption due to simplified dosing regimens and improved patient compliance; preferred in emerging markets.

By Disease Type

Latent TB Type - ~35% share

Increasing screening and preventive treatment programs globally; strong demand in North America and Europe.

Active TB Type - ~65% share

Drives majority of drug consumption; high prevalence in Asia-Pacific, Africa, and South America.

By Route of Administration

Parenteral - ~30% share

Primarily used in hospitals for severe TB cases; intravenous therapy ensures rapid drug delivery.

Oral - ~70% share

Dominates market due to ease of use, patient compliance, and outpatient treatment suitability.

By Distribution Channel

Hospital Pharmacy - ~60% share

Major channel for inpatient and severe TB treatments; preferred for first-line and parenteral therapies.

Retail Pharmacy - ~40% share

Increasing share due to outpatient prescriptions, combination therapies, and preventive treatment.

By Region

North America - ~20% share

Focus on latent TB prevention and drug-resistant cases; well-established healthcare infrastructure supports therapy access.

Europe - ~15% share

Government-funded TB programs; growing adoption of combination drug therapies.

Asia-Pacific - ~40% share

Highest burden of active TB; strong market for first-line and combination therapies.

South America - ~10% share

Moderate market growth; adoption driven by public health initiatives and rising awareness.

Middle East & Africa - ~15% share

Increasing government initiatives to combat TB; strong demand for both first-line and second-line therapies.

FAQ

What is the current size of the Tuberculosis drug Market?

A: In 2024, the Tuberculosis drug Market was valued at US$ 2.45 Billion , reflecting its strong industry presence.

Q2: How large is the Tuberculosis drug Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Tuberculosis drug Market will grow to around US$ 3.78 Billion, demonstrating significant expansion.

Q3: What is the growth rate of the Tuberculosis drug Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 4.9% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.